Cingulate partners with Indegene for ADHD therapy

Cingulate partners with Indegene for ADHD therapy
https://www.pharmaceutical-technology.com
Published onhttps://www.pharmaceutical-technology.com
Publish Date31 March 2023
Reading time1 Min

Share on Social Links

Category

StockBeginner GuideAngel InvestingSME IPOEconomy MarketAIFInvestmentsMore

B iopharmaceutical firm Cingulate and life sciences commercialisation firm Indegene have entered into a joint commercialisation deal for the former's attention-deficit/ hyperactivity disorder (ADHD) therapy CTx-1301 (dexmethylphenidate). The agreement is intended for providing commercial support for CTx-1301, after receiving the US Food and Drug Administration (FDA) approval. It covers cross-functional services through an omnichannel marketing approach designed for the management of the pre-commercial support during the Phase Ill clinical trials as well as the nationwide commercialisation of CTx-1301. The new investigational treatment CTx-1301 is being developed as a once-daily stimulant medication for the treatment of ADHD. cently, Cingulate commenced its first Phase Ill trial which has been designed for evaluating CTx-1301's fety and efficacy.

Tags

StockBeginner GuideAngel InvestingSME IPOEconomy MarketAIFInvestmentsMore

Stay Connected, Stay Informed –

Join Our

WhatsApp

Channel!

Don’t miss out on exclusive updates, market trends, and real-time investment opportunities. Be the first to know about the latest unlisted stocks, IPO announcements, and curated Fact Sheets, delivered straight to your WhatsApp.

Pre Ipo

Pre Ipo

Upcoming IPO

Upcoming IPO

Unicorn

Unicorn